Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors

Shusaku Mizukami, Chiaki Kajiwara, Hiroshi Ishikawa, Ichiro Katayama, Katsuyuki Yui, Heiichiro Udono

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Vaccination with heat shock proteins (HSP) protects mice from challenge with the tumor from which the HSP were isolated. The antigenicity of HSP vaccination is thought to result from HSP-associated endogenous major histocompatibility complex class I peptides or their precursors. The vaccination effect can be achieved in an adjuvant-free manner and is mediated by CD8+ T cells, indicating that HSP can act as a natural adjuvant and cross-prime T cells in vivo. We previously devised a recombinant vaccine composed of a CD8+ T cell epitope fused to the carboxyl-terminus of hsc70 and demonstrated efficient generation of antigen-specific cytotoxic T lymphocyte (CTL) after vaccination with a few micrograms of the hsc70-CTL epitope fusion protein. The present study aimed to determine if the fusion protein vaccine could control tumor growth in vivo and whether simultaneous fusion of a CD4+ T cell epitope to the amino terminus of the hsc70-CTL epitope would be a more potent vaccine compared to the CTL epitope alone. Ovalbumin (OVA)-derived 8 mer peptide, OVA257-264′, and 16mer peptide, OVA265-280, were used as CD8+ and CD4+ T cell epitopes, respectively. Vaccination with hsc70-OVA257-264 generated peptide specific CTL more effectively than a peptide plus incomplete Freund's adjuvant combination, and suppressed growth of OVA expressing EL4 (E.G7) and B16 melanoma tumor cells. Addition of OVA265-280 to the amino-terminus of hsc70-OVA257-264 (OVA265-280 -hsc70-OVA257-264) enhanced the generation of the OVA257-264-specific CTL population, leading to better eradication of MO5 lung metastasis compared to hsc70-OVA257-264′. Our results suggest that fusion of both CD4+ and CD8+ T cell epitopes to hsc70 enhances tumor immunity beyond the effect of the CD8+ T cell epitope alone.

Original languageEnglish
Pages (from-to)1008-1015
Number of pages8
JournalCancer Science
Volume99
Issue number5
DOIs
Publication statusPublished - May 2008
Externally publishedYes

Fingerprint

HSC70 Heat-Shock Proteins
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Heat-Shock Proteins
Vaccination
Neoplasms
Peptides
Ovalbumin
Vaccines
T-Lymphocytes
Experimental Melanomas
Synthetic Vaccines
Growth
Major Histocompatibility Complex
Immunity
Proteins
Neoplasm Metastasis
Antigens
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. / Mizukami, Shusaku; Kajiwara, Chiaki; Ishikawa, Hiroshi; Katayama, Ichiro; Yui, Katsuyuki; Udono, Heiichiro.

In: Cancer Science, Vol. 99, No. 5, 05.2008, p. 1008-1015.

Research output: Contribution to journalArticle

Mizukami, Shusaku ; Kajiwara, Chiaki ; Ishikawa, Hiroshi ; Katayama, Ichiro ; Yui, Katsuyuki ; Udono, Heiichiro. / Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. In: Cancer Science. 2008 ; Vol. 99, No. 5. pp. 1008-1015.
@article{5d6c61affbdc4179b78e3dfeb919c239,
title = "Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors",
abstract = "Vaccination with heat shock proteins (HSP) protects mice from challenge with the tumor from which the HSP were isolated. The antigenicity of HSP vaccination is thought to result from HSP-associated endogenous major histocompatibility complex class I peptides or their precursors. The vaccination effect can be achieved in an adjuvant-free manner and is mediated by CD8+ T cells, indicating that HSP can act as a natural adjuvant and cross-prime T cells in vivo. We previously devised a recombinant vaccine composed of a CD8+ T cell epitope fused to the carboxyl-terminus of hsc70 and demonstrated efficient generation of antigen-specific cytotoxic T lymphocyte (CTL) after vaccination with a few micrograms of the hsc70-CTL epitope fusion protein. The present study aimed to determine if the fusion protein vaccine could control tumor growth in vivo and whether simultaneous fusion of a CD4+ T cell epitope to the amino terminus of the hsc70-CTL epitope would be a more potent vaccine compared to the CTL epitope alone. Ovalbumin (OVA)-derived 8 mer peptide, OVA257-264′, and 16mer peptide, OVA265-280, were used as CD8+ and CD4+ T cell epitopes, respectively. Vaccination with hsc70-OVA257-264 generated peptide specific CTL more effectively than a peptide plus incomplete Freund's adjuvant combination, and suppressed growth of OVA expressing EL4 (E.G7) and B16 melanoma tumor cells. Addition of OVA265-280 to the amino-terminus of hsc70-OVA257-264 (OVA265-280 -hsc70-OVA257-264) enhanced the generation of the OVA257-264-specific CTL population, leading to better eradication of MO5 lung metastasis compared to hsc70-OVA257-264′. Our results suggest that fusion of both CD4+ and CD8+ T cell epitopes to hsc70 enhances tumor immunity beyond the effect of the CD8+ T cell epitope alone.",
author = "Shusaku Mizukami and Chiaki Kajiwara and Hiroshi Ishikawa and Ichiro Katayama and Katsuyuki Yui and Heiichiro Udono",
year = "2008",
month = "5",
doi = "10.1111/j.1349-7006.2008.00788.x",
language = "English",
volume = "99",
pages = "1008--1015",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors

AU - Mizukami, Shusaku

AU - Kajiwara, Chiaki

AU - Ishikawa, Hiroshi

AU - Katayama, Ichiro

AU - Yui, Katsuyuki

AU - Udono, Heiichiro

PY - 2008/5

Y1 - 2008/5

N2 - Vaccination with heat shock proteins (HSP) protects mice from challenge with the tumor from which the HSP were isolated. The antigenicity of HSP vaccination is thought to result from HSP-associated endogenous major histocompatibility complex class I peptides or their precursors. The vaccination effect can be achieved in an adjuvant-free manner and is mediated by CD8+ T cells, indicating that HSP can act as a natural adjuvant and cross-prime T cells in vivo. We previously devised a recombinant vaccine composed of a CD8+ T cell epitope fused to the carboxyl-terminus of hsc70 and demonstrated efficient generation of antigen-specific cytotoxic T lymphocyte (CTL) after vaccination with a few micrograms of the hsc70-CTL epitope fusion protein. The present study aimed to determine if the fusion protein vaccine could control tumor growth in vivo and whether simultaneous fusion of a CD4+ T cell epitope to the amino terminus of the hsc70-CTL epitope would be a more potent vaccine compared to the CTL epitope alone. Ovalbumin (OVA)-derived 8 mer peptide, OVA257-264′, and 16mer peptide, OVA265-280, were used as CD8+ and CD4+ T cell epitopes, respectively. Vaccination with hsc70-OVA257-264 generated peptide specific CTL more effectively than a peptide plus incomplete Freund's adjuvant combination, and suppressed growth of OVA expressing EL4 (E.G7) and B16 melanoma tumor cells. Addition of OVA265-280 to the amino-terminus of hsc70-OVA257-264 (OVA265-280 -hsc70-OVA257-264) enhanced the generation of the OVA257-264-specific CTL population, leading to better eradication of MO5 lung metastasis compared to hsc70-OVA257-264′. Our results suggest that fusion of both CD4+ and CD8+ T cell epitopes to hsc70 enhances tumor immunity beyond the effect of the CD8+ T cell epitope alone.

AB - Vaccination with heat shock proteins (HSP) protects mice from challenge with the tumor from which the HSP were isolated. The antigenicity of HSP vaccination is thought to result from HSP-associated endogenous major histocompatibility complex class I peptides or their precursors. The vaccination effect can be achieved in an adjuvant-free manner and is mediated by CD8+ T cells, indicating that HSP can act as a natural adjuvant and cross-prime T cells in vivo. We previously devised a recombinant vaccine composed of a CD8+ T cell epitope fused to the carboxyl-terminus of hsc70 and demonstrated efficient generation of antigen-specific cytotoxic T lymphocyte (CTL) after vaccination with a few micrograms of the hsc70-CTL epitope fusion protein. The present study aimed to determine if the fusion protein vaccine could control tumor growth in vivo and whether simultaneous fusion of a CD4+ T cell epitope to the amino terminus of the hsc70-CTL epitope would be a more potent vaccine compared to the CTL epitope alone. Ovalbumin (OVA)-derived 8 mer peptide, OVA257-264′, and 16mer peptide, OVA265-280, were used as CD8+ and CD4+ T cell epitopes, respectively. Vaccination with hsc70-OVA257-264 generated peptide specific CTL more effectively than a peptide plus incomplete Freund's adjuvant combination, and suppressed growth of OVA expressing EL4 (E.G7) and B16 melanoma tumor cells. Addition of OVA265-280 to the amino-terminus of hsc70-OVA257-264 (OVA265-280 -hsc70-OVA257-264) enhanced the generation of the OVA257-264-specific CTL population, leading to better eradication of MO5 lung metastasis compared to hsc70-OVA257-264′. Our results suggest that fusion of both CD4+ and CD8+ T cell epitopes to hsc70 enhances tumor immunity beyond the effect of the CD8+ T cell epitope alone.

UR - http://www.scopus.com/inward/record.url?scp=43649104764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43649104764&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00788.x

DO - 10.1111/j.1349-7006.2008.00788.x

M3 - Article

C2 - 18341654

AN - SCOPUS:43649104764

VL - 99

SP - 1008

EP - 1015

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -